Daratumumab Triplets Recommended for EU Approval in Myeloma

February 24th, 2017 – The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of daratumumab in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone for patients with relapsed multiple myeloma following at least 1 prior therapy, based on findings from the phase III POLLUX and CASTOR studies.1,2 The positive opinion will now be reviewed by the European Commission and a final … (leggi tutto)